Nasdaq
$63.20▼ 3.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.08BShares out 48.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.9After-hours26.10.10 05:134Ownership#●●●
Celcuity Inc.
Insider Leo Furcht of Celcuity Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of October 7, 2026. This filing serves as an official notification of the insider's equity transaction.…more
$63.20-3.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 06:084Ownership
Celcuity Inc.
Insider David W. Gryska of Celcuity Inc. reported a change in beneficial ownership of securities as of October 1, 2026. This Form 4 filing discloses the update regarding the insider's equity holdings.…more
$63.20-3.25%vs prev closeView filingShare - 10.5After-hours26.10.06 06:063Ownership
Celcuity Inc.
David W. Gryska, an officer of Celcuity Inc., has filed a Power of Attorney authorizing designated representatives to handle SEC reporting obligations on his behalf. This filing facilitates the timely submission of required regulatory documents, including Forms 3, 4, 5, and Form 144, in compliance with the Securities Exchange Act.…more
$63.20-3.25%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoClosed26.10.24 17:15#●●●#●●●
Celcuity Reports Positive Phase 3 Data for Gedatolisib in Breast Cancer…more
Celcuity announced updated Phase 3 VIKTORIA-1 study results showing improved progression-free survival and response duration for its gedatolisib regimens compared to standard care. The data highlights significant clinical benefits and a favorable safety profile in patients with HR+/HER2- advanced breast cancer.…more
$63.20-3.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 1d agoPre-market26.10.23 22:15
●●●●●●●● ●●●●● ●●●●●●
Celcuity announced positive progression-free survival data from its Phase 1b/2 study evaluating gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer. The company plans to initiate the Phase 2 portion of the study in the first half of 2027.…more
$63.20-3.25%vs prev close - 10.5Pre-market26.10.05 21:00
●●●●●●●● ●●●●● ●●●●●●
Celcuity announced it will present clinical trial data for its therapeutic candidate, gedatolisib, at the upcoming ESMO 2026 Congress. While the presentations aim to showcase clinical progress in breast and prostate cancer, the impact remains neutral until specific results are disclosed.…more
$63.20-3.25%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report